The Nontoxic Cell Cycle Modulator Indirubin Augments Transduction of Adeno-Associated Viral Vectors and Zinc-Finger Nuclease-Mediated Gene Targeting
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Parameters that regulate or affect the cell cycle or the DNA repair choice between non-homologous end-joining and homology-directed repair (HDR) are excellent targets to enhance therapeutic gene targeting. Here, we have evaluated the impact of five cell-cycle modulating drugs on targeted genome engineering mediated by DNA double-strand break (DSB)-inducing nucleases, such as zinc-finger nucleases (ZFNs). For a side-by-side comparison, we have established four reporter cell lines by integrating a mutated EGFP gene into either three transformed human cell lines or primary umbilical cord–derived mesenchymal stromal cells (UC-MSCs). After treatment with different cytostatic drugs, cells were transduced with adeno-associated virus (AAV) vectors that encode a nuclease or a repair donor to rescue EGFP expression through DSB-induced HDR. We show that transient cell-cycle arrest increased AAV transduction and AAV-mediated HDR up to six-fold in human cell lines and ten-fold in UC-MSCs, respectively. Targeted gene correction was observed in up to 34% of transduced cells. Both the absolute and the relative gene-targeting frequencies were dependent on the cell type, the cytostatic drug, the vector dose, and the nuclease. Treatment of cells with the cyclin-dependent kinase inhibitor indirubin-3′-monoxime was especially promising as this compound combined high stimulatory effects with minimal cytotoxicity. In conclusion, indirubin-3′-monoxime significantly improved AAV transduction and the efficiency of AAV/ZFN-mediated gene targeting and may thus represent a promising compound to enhance DSB-mediated genome engineering in human stem cells, such as UC-MSCs, which hold great promise for future clinical applications. Rahman and colleagues evaluate the impact of five cell cycle-modulating drugs on targeted genome engineering mediated by zinc-finger nucleases (ZFNs). They show that treatment of cells with the cyclin-dependent kinase inhibitor indirubin-3′-monoxime is especially promising as this compound significantly improves AAV transduction and the efficiency of AAV/ZFN-mediated gene targeting in vitro.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genome editing with engineered zinc finger nucleases
Urnov, F. D., Rebar, E. J., Holmes, M. C., Zhang, H. S., & Gregory, P. D. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2842 · Cited by 2,285
Regulation of DNA double-strand break repair pathway choice
Shrivastav, M., De Haro, L. P., & Nickoloff, J. A. (2008) · Cell Research · doi:10.1038/cr.2007.111 · Cited by 1,329
Genome Engineering With Zinc-Finger Nucleases
Carroll, D. (2011) · Genetics · doi:10.1534/genetics.111.131433 · Cited by 1,076
TAL effectors: customizable proteins for DNA targeting
Bogdanove, A. J., & Voytas, D. F. (2011) · Science · doi:10.1126/science.1204094 · Cited by 984
Lombardo, A., Genovese, P., Beausejour, C. M., Colleoni, S., Lee, Y.-L., Kim, K. A., Ando, D., Urnov, F. D., Galli, C., Gregory, P. D., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1353 · Cited by 845 · cited 2×
“When employing designer ZFNs, gene conversion frequencies of up to 50% were reported in human cell lines in the absence of selection (Lombardo et al., 2007; Maeder et al., 2008).”
Structure-based redesign of the dimerization interface reduces the toxicity of zinc-finger nucleases
Szczepek, M., Brondani, V., Büchel, J., Serrano, L., Segal, D. J., & Cathomen, T. (2007) · Nature Biotechnology · doi:10.1038/nbt1317 · Cited by 501 · cited 3×
“All other plasmids have been described before: plasmids encoding AAV vector in Gellhaus et al. (2010); ZFN expression plasmids in Alwin et al. (2005) and Szczepek et al. (2007); and control vector pRK5.”
Self-citationLi, W., Asokan, A., Wu, Z., Van Dyke, T., DiPrimio, N., Johnson, J. S., Govindaswamy, L., Agbandje-McKenna, M., Leichtle, S., Eugene Redmond Jr, D., et al. (2008) · Molecular Therapy · doi:10.1038/mt.2008.100 · Cited by 261
Custom zinc-finger nucleases for use in human cells
Alwin, S., Gere, M. B., Guhl, E., Effertz, K., Barbas, C. F., Segal, D. J., Weitzman, M. D., & Cathomen, T. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.06.094 · Cited by 165
Monahan, P. E., Lothrop, C. D., Sun, J., Hirsch, M. L., Kafri, T., Kantor, B., Sarkar, R., Tillson, D. M., Elia, J. R., & Samulski, R. J. (2010) · Molecular Therapy · doi:10.1038/mt.2010.170 · Cited by 125 · cited 2×
“, 2008), as well as the use of compounds that do not directly damage the DNA, such as proteasome inhibitors ( Jennings et al., 2005; Monahan et al., 2010), have further improved AAV transduction efficiencies both in cultured cells (Ellis et al.”
Asuri, P., Bartel, M. A., Vazin, T., Jang, J.-H., Wong, T. B., & Schaffer, D. V. (2012) · Molecular Therapy · doi:10.1038/mt.2011.255 · Cited by 119 · cited 1×
“…gene targeting in other multipotent (Chamberlain et al., 2004; Jang et al., 2011) or pluripotent stem cells (Mitsui et al., 2009; Khan et al., 2010; Asuri et al., 2012), respectively, as well as in vivo (Papado-poulos et al., 1997; Paulk et al., 2012), these findings present a promising strategy to…”
Targeted Genome Modifications Using Integrase-deficient Lentiviral Vectors
Cornu, T. I., & Cathomen, T. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300345 · Cited by 105 · cited 2×
“696, U2OS.696, and UC-MSC.696 were generated by lentiviral transduction as previously described (Cornu and Cathomen, 2007; Gellhaus et al., 2010).”
MethodSelf-citationCervelli, T., Palacios, J. A., Zentilin, L., Mano, M., Schwartz, R. A., Weitzman, M. D., & Giacca, M. (2008) · Journal of Cell Science · doi:10.1242/jcs.003632 · Cited by 84 · cited 1×
“This effect has been attributed to activation of the cellular DNA damage response, which in turn is important to process the vector genome to generate a transcription-competent template (Cervelli et al., 2008).”
Cited by
Small molecules enhance CRISPR genome editing in pluripotent stem cells
Yu, C., Liu, Y., Ma, T., Liu, K., Xu, S., Zhang, Y., Liu, H., La Russa, M., Xie, M., Ding, S., et al. (2015) · Cell stem cell · doi:10.1016/j.stem.2015.01.003 · Cited by 455
Adenoviral vector DNA for accurate genome editing with engineered nucleases
Holkers, M., Maggio, I., Henriques, S. F. D., Janssen, J. M., Cathomen, T., & Gonçalves, M. A. F. V. (2014) · Nature Methods · doi:10.1038/nmeth.3075 · Cited by 138
Self-citationDelivery and therapeutic applications of gene editing technologies ZFNs, TALENs, and CRISPR/Cas9
LaFountaine, J. S., Fathe, K., & Smyth, H. D. C. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.08.029 · Cited by 111
Concerns regarding ‘off-target’activity of genome editing endonucleases
Kadam, U. S., Shelake, R. M., Chavhan, R. L., & Suprasanna, P. (2018) · Plant Physiology and Biochemistry · doi:10.1016/j.plaphy.2018.03.027 · Cited by 47
Wang, Y., Wang, Y., Chang, T., Huang, H., & Yee, J.-K. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1057 · Cited by 26
Metadata
- Authors
- Rahman, S. H., Bobis-Wozowicz, S., Chatterjee, D., Gellhaus, K., Pars, K., Heilbronn, R., Jacobs, R., & Cathomen, T.
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 2013-01
- Volume
- 24
- Issue
- 1
- Pages
- 67-77
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- OpenAlex
- W2017791362
- Cited by
- 39
- References
- 12
- FWCI
- 2.48
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.